JCI Insight Impact Factor

The current exact-title JCR-derived record shows 6.8, released June 17, 2026 and based on 2025 citation data. ASCI's own about page also displays 6.8, but public pages can use different year labels for the metric or lag behind the JCR release. Secondary directories may show Scopus impact score, SJR, h-index, or CiteScore beside the JIF, and those numbers are not interchangeable.

Source limitation: this page uses the exact-title current JCR-derived record for the 6.8 JIF, and uses publisher pages for author-facing mechanics. Do not cite SJR, CiteScore, h-index, or Scopus impact score as if they were Journal Impact Factor values.

The current JIF is up from 6.1 to 6.8 in the exact-title current record. The longer pattern is more mixed: JCI Insight rose quickly after launch, reached a pandemic-era citation high, then normalized while remaining a Q1 translational-medicine journal. That makes the trend useful for context, but not precise enough to cite without direct JCR access.

Trend guardrail: JCI Insight is young enough that older year-by-year tables can mix first JIF, Scopus impact score, rounded JIF, and current-release JIF rows. Use 2025 and 2024 for current source-bound comparison; use direct JCR access for formal historical year-by-year reporting.

JCI Insight is Q1 in the current Medicine, Research & Experimental JCR-derived record. Secondary rankings also place it in Q1 medical categories, but exact rank positions depend on the source system and field grouping.

For formal use, verify the exact JCR category rank and percentile directly in Journal Citation Reports. For submission strategy, the more important point is simpler: JCI Insight is a Q1 society journal, but it is not a prestige shortcut around JCI Insight's broad physician-scientist readership filter.

A 6.8 JIF tells you that JCI Insight is a real Q1 translational-medicine venue with a meaningful citation footprint, not a low-stakes fallback. It also tells you that the journal sits below flagship JCI, Nature Medicine, Science Translational Medicine, and several broader high-priority translational journals by citation density. That difference matters because the editorial model is different.

JCI Insight is useful when the manuscript has genuine clinical or translational weight but does not honestly belong at the very top of the JCI-style mechanism-and-disease ladder. The metric should not be read as "JCI, easier." It should be read as "ASCI readership, broader acceptance of clinically relevant basic and translational work, still requiring a clear contribution to biology or disease treatment."

In practical terms, the 6.8 JIF helps a paper that already has the right audience. It does not fix a narrow subspecialty story, a mouse-only mechanism paper with decorative human data, or a cohort association with no biological or treatment interpretation. The author's question should be: can a physician-scientist outside the immediate subspecialty understand why this finding changes disease understanding or treatment logic?

In our pre-submission review work on JCI Insight manuscripts, the recurring problem is not usually whether the science is real. The stronger signal is whether the abstract, first figures, methods, human or disease evidence, article category, and cover letter make a broad physician-scientist case early. Manusights guide-build evidence units for this page combine the metric-source ledger above with repeated JCI Insight fit patterns we see before upload.

JCI Insight subspecialty paper wearing a translational label. We often see a technically solid manuscript where every important sentence is legible only to one disease niche, cell-type community, or assay subfield. JCI Insight can publish specialized work, but the first read still has to show why a broad biomedical reader should care. The abstract, Figure 1, and cover letter need to name the biology or disease consequence before narrow technical detail takes over.

JCI Insight biomarker paper where association is the whole claim. A clinical cohort, omics signal, protein marker, or imaging feature is not enough by itself. JCI Insight's stated standard is meaningful contribution to understanding biology or disease treatment. A biomarker story needs to say what the signal teaches, what decision it informs, or what mechanism it reflects. Otherwise, the paper often belongs in a disease-specialty clinical journal.

JCI Insight model-first mechanism with human evidence appended late. Preclinical models and human-derived materials are within scope. The weak pattern is a rodent or cell-line mechanism study where the human component appears as a late validation panel and does not change the argument. For JCI Insight, human, disease, or clinical evidence should be load-bearing, not cosmetic.

JCI Insight category mismatch. Some manuscripts are better shaped as Research Letters, Resource and Technical Advances, or specialty clinical papers than as full Research submissions. If the category makes the evidence look thin, the metric will not help. The selected article type should match the length, display-item logic, methods depth, and central claim.

A JCI Insight readiness check can test whether the abstract, figure sequence, human evidence, methods, category, and cover letter support this target before upload.

Use official ASCI pages for mechanics, and use the fit logic above to decide whether the impact factor supports the target.

JCI Insight at 6.8 is a strong Q1 signal for clinical investigation and translational biomedical work. The number is also modest enough to make the journal easy to misread: it is not a weak fallback, and it is not a shortcut around JCI Insight's readership and field-advance filter.

The best use of the metric is to calibrate a real manuscript-routing decision. If the paper has disease relevance, meaningful biology or treatment logic, and an argument that travels beyond one narrow specialty, JCI Insight can be a clean ASCI target. If the paper is mainly a narrow association, a model-only mechanism, or a specialty clinical story, a lower or different journal can be a better strategic fit even if the JIF is less attractive.